Excitotoxicity

Introduction

Excitotoxicity is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Excitotoxicity^{1Olney, 19691969 · DOI 10.1126/science.164.3880.719Open reference} is a pathological ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference} process in which neurons are damaged and destroyed by the overactivation of receptors for the excitatory neurotransmitter glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}. First described by John Olney in 1969 when he observed that monosodium glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference} caused retinal neuron death in neonatal mice, excitotoxicity is now recognized as a central ^{319951995 · DOI 10.1016/0306-4522(95Open reference} mechanism of neuronal injury in stroke, traumatic brain injury, and multiple neurodegenerative diseases including Alzheimer’s Disease, amyotrophic ^{419981998 · DOI 10.1016/s0896-6273(00Open reference} lateral sclerosis (ALS), and Huntington’s Disease Olney, 1969. The term captures the paradox that ^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference} glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}, the brain’s most abundant excitatory neurotransmitter and an essential ^{620022002 · DOI 10.1016/S0896-6273(02Open reference} mediator of synaptic plasticity and learning, becomes a potent neurotoxin when present in excess. ^{720042004 · DOI 10.1038/427801aOpen reference}

Historical Discovery

John Olney’s seminal 1969 study demonstrated that subcutaneous injection of monosodium glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}0 in neonatal mice produced acute neuronal necrosis in the arcuate nucleus of the ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}1 hypothalamus, along with retinal degeneration and obesity Olney, 1969. He coined the term ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}2 “excitotoxicity” to describe this phenomenon. Dennis Choi extended this work in the 1980s by demonstrating that glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}3-mediated neuronal death in cortical cell cultures was calcium-dependent and mediated ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}4 primarily through NMDA receptors ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}5, ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}6 establishing the calcium overload hypothesis that remains central to the field Choi, 1992. These discoveries ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}7 established the conceptual framework linking excessive glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}8rgic transmission to ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}9 neurodegeneration. ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}0

Molecular Mechanism

Glutamate Receptor Overactivation

Under pathological conditions such as ischemia, trauma, or chronic neurodegeneration, extracellular glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}1 concentrations rise dramatically due to excessive presynaptic release, impaired reuptake by astrocytic transporters, or reversal of glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}2 transporters during energy failure. This triggers sustained activation of three classes of ionotropic glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}3 receptors: ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}4

• NMDA receptors ^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}5: Highly calcium-permeable channels composed of GluN1 and GluN2 (A-D) subunits. Under normal conditions, a voltage-dependent magnesium block limits ion flux, but sustained depolarization relieves this block, permitting massive calcium entry. NMDA receptors are the primary mediators of excitotoxic calcium influx Bhatt et al., 2009.

• AMPA^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}6 receptors: Mediate fast excitatory transmission. Most AMPA^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}7 receptors contain the GluA2 subunit, which renders them calcium-impermeable. However, neurons lacking GluA2 (due to impaired RNA editing or altered subunit expression) possess calcium-permeable AMPA^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}8 receptors that contribute directly to excitotoxic injury Kawahara et al., 2004.

• Kainate receptors: Contribute to excitotoxicity through both ionotropic calcium flux and metabotropic signaling that modulates glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}9 release.

Calcium Overload and Downstream Cascades

The defining event in excitotoxicity is pathological elevation of intracellular calcium concentration, which rises from a resting level of approximately 100 nM to low micromolar ranges. This calcium overload activates multiple destructive cascades Bhatt et al., 2009:

• calpains: Calcium-activated cysteine proteases that cleave cytoskeletal proteins (spectrin, MAP2), signaling molecules, and membrane receptors. Calpain activation is an early marker of excitotoxic injury and contributes to both necrotic and apoptotic cell death. Calpain also converts xanthine dehydrogenase to xanthine oxidase, generating reactive oxygen species.

• Calcineurin (protein phosphatase 2B): Calcium/calmodulin-dependent phosphatase that dephosphorylates the pro-apoptotic protein BAD, promoting its translocation to mitochondria and triggering apoptotic signaling.

• Neuronal nitric oxide synthase (nNOS): Calcium/calmodulin-dependent enzyme physically tethered to NMDA receptor^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}0 receptors] via PSD-95. [Overactivation produces excessive nitric oxide (NO), which reacts with superoxide to form peroxynitrite (ONOO^-), a potent oxidant that damages proteins, lipids, and DNA, and inhibits mitochondrial complex I and IV Wang et al., 2014.

• Mitochondrial permeability transition: Excessive mitochondrial calcium uptake triggers opening of the mitochondrial permeability transition pore (mPTP), collapsing the membrane potential, halting ATP synthesis, and releasing cytochrome c and apoptosis-inducing factor into the cytoplasm Bhatt et al., 2009. This links calcium overload directly to both necrotic (energy failure) and apoptotic cell death pathways.

Synaptic vs. Extrasynaptic NMDA Receptor Dichotomy

A transformative concept in excitotoxicity research emerged from the work of Hardingham and Bading, who demonstrated that the subcellular location of NMDA receptor^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}1 receptor activation determines whether the outcome is neuroprotective or neurotoxic Hardingham & Bading, 2010:

• Synaptic NMDA receptor](/proteins/nmda-receptor)^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}2 receptors (enriched in GluN2A subunits): Activation by physiological synaptic transmission engages the Ras-ERK-CREB pathway, promotes BDNF expression, upregulates antioxidant defenses (including thioredoxin and superoxide dismutase), and builds a neuroprotective “shield” against subsequent insults.

• Extrasynaptic NMDA^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}3 receptors (enriched in GluN2B subunits): Activated by glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}4 spillover during pathological conditions. Extrasynaptic activation shuts off CREB signaling, activates the FOXO transcription factor and pro-death gene expression, triggers mitochondrial depolarization, and promotes calpain-mediated cleavage of the phosphatase STEP, amplifying excitotoxic cascades Hardingham & Bading, 2010.

This dichotomy has profound therapeutic implications: global NMDA^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}5 receptor blockade eliminates both pro-survival and pro-death signaling, whereas selective inhibition of extrasynaptic GluN2B-containing receptors could preserve physiological signaling while blocking excitotoxicity Parsons & Raymond, 2014.

Excitotoxicity in Stroke and Ischemia

Excitotoxicity^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}6 is the primary mechanism of acute neuronal death following ischemic stroke. Within minutes of vessel occlusion, ATP depletion causes failure of the Na+/K+-ATPase pump, neuronal depolarization, and uncontrolled release of glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}7 into the extracellular space. Simultaneously, energy failure impairs astrocytic glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}8 transporters (EAAT1/EAAT2) and may even reverse their function, further elevating extracellular glutamate^{2Choi, 19921992 · DOI 10.1002/neu.480231003Open reference}9 to neurotoxic concentrations exceeding 100 micromolar. The resulting NMDA receptor^{319951995 · DOI 10.1016/0306-4522(95Open reference}0 receptor] overactivation, calcium influx, and mitochondrial dysfunction produce a core of necrotic tissue (infarct) surrounded by a penumbral zone of delayed excitotoxic injury Bhatt et al., 2009.

Excitotoxicity in Alzheimer’s Disease

In Alzheimer’s Disease, amyloid-beta (Aβ oligomers directly enhance excitotoxic vulnerability through multiple mechanisms. Soluble Aβ oligomers bind to GluN2B-containing extrasynaptic NMDA receptor^{319951995 · DOI 10.1016/0306-4522(95Open reference}1 receptors], increasing extrasynaptic calcium influx and inhibiting synaptic NMDA^{319951995 · DOI 10.1016/0306-4522(95Open reference}2 receptor-dependent long-term potentiation (LTP). Abeta also impairs glutamate^{319951995 · DOI 10.1016/0306-4522(95Open reference}3 reuptake by astrocytes, elevating ambient glutamate^{319951995 · DOI 10.1016/0306-4522(95Open reference}4 levels, and induces internalization of synaptic NMDA^{319951995 · DOI 10.1016/0306-4522(95Open reference}5 receptors while promoting extrasynaptic receptor trafficking Li et al., 2011. The resulting shift from synaptic to extrasynaptic NMDA^{319951995 · DOI 10.1016/0306-4522(95Open reference}6 receptor activation suppresses CREB-dependent survival gene expression and promotes tau] hyperphosphorylation, linking excitotoxicity to tau] protein] pathology. This mechanistic understanding provides the rationale for memantine use in moderate-to-severe AD.

Excitotoxicity in ALS

Glutamate excitotoxicity is a central pathogenic mechanism in amyotrophic lateral sclerosis. Motor neurons are particularly vulnerable due to their large soma size, high density of calcium-permeable AMPA^{319951995 · DOI 10.1016/0306-4522(95Open reference}7 receptors (resulting from low GluA2 expression), and high metabolic demands. A critical feature of ALS pathology is the loss of the astrocytic glutamate^{319951995 · DOI 10.1016/0306-4522(95Open reference}8 transporter EAAT2 (GLT-1), which normally clears approximately 90% of synaptic glutamate^{319951995 · DOI 10.1016/0306-4522(95Open reference}9. Post-mortem studies show a 30-95% reduction in EAAT2 protein in the motor cortex and spinal cord of ALS patients, attributable to aberrant RNA splicing, oxidative damage, and caspase-3-mediated cleavage Rothstein et al., 1995; Lin et al., 1998. Riluzole, the first FDA-approved ALS therapy, extends median survival by 2-3 months through multiple anti-excitotoxic mechanisms: inhibition of presynaptic glutamate^{419981998 · DOI 10.1016/s0896-6273(00Open reference}0 release, blockade of voltage-gated sodium channels, and modest antagonism of NMDA^{419981998 · DOI 10.1016/s0896-6273(00Open reference}1 receptors Bellingham, 2011.

Excitotoxicity in Huntington’s Disease

Medium spiny neurons (MSNs) of the striatum, the cell population most vulnerable in Huntington’s Disease, are exquisitely sensitive to NMDA^{419981998 · DOI 10.1016/s0896-6273(00Open reference}2 receptor-mediated excitotoxicity. Mutant huntingtin (mHTT) enhances excitotoxic vulnerability through several mechanisms: mHTT directly interacts with GluN2B-containing NMDA receptor^{419981998 · DOI 10.1016/s0896-6273(00Open reference}3 receptors], potentiating receptor currents; mHTT impairs binding to PSD-95, freeing PSD-95 to stabilize more GluN2B-containing receptors at the synapse; mHTT sensitizes mitochondria to calcium-induced depolarization, lowering the threshold for mPTP opening; and mHTT disrupts EAAT2 expression in surrounding astrocytes Bhatt et al., 2009; Zeron et al., 2002. Injection of the NMDA^{419981998 · DOI 10.1016/s0896-6273(00Open reference}4 receptor agonist quinolinic acid into the rodent striatum faithfully reproduces the selective MSN loss and chorea-like motor phenotype of HD, further supporting the excitotoxicity hypothesis.

Therapeutic Approaches

Agent	Mechanism	Indication	Status	Key Outcome
Memantine	Low-affinity, voltage-dependent, open-channel NMDA419981998 · DOI 10.1016/s0896-6273(00Open reference5 receptor blocker; preferentially blocks tonically activated extrasynaptic receptors	Moderate-to-severe AD	FDA-approved (2003)	Modest cognitive benefit; does not disrupt normal synaptic transmission
Riluzole	Inhibits glutamate419981998 · DOI 10.1016/s0896-6273(00Open reference6 release; blocks voltage-gated Na+ channels; weak NMDA419981998 · DOI 10.1016/s0896-6273(00Open reference7 antagonism	ALS	FDA-approved (1995)	Extends median survival by 2-3 months
Selfotel (CGS 19755)	Competitive NMDA419981998 · DOI 10.1016/s0896-6273(00Open reference8 antagonist	Acute stroke	Failed Phase III	No efficacy; psychotomimetic side effects; trial stopped for futility
Aptiganel (Cerestat)	Non-competitive NMDA419981998 · DOI 10.1016/s0896-6273(00Open reference9 channel blocker	Acute stroke	Failed Phase III	Worse outcomes in treatment group; hypertension and sedation
Gavestinel (GV150526)	Glycine-site NMDA5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference0 antagonist	Acute stroke	Failed Phase III (GAIN trial)	No benefit vs. placebo at 3 months
Perampanel	Selective non-competitive AMPA5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference1 receptor antagonist	Epilepsy; ALS trials	FDA-approved for epilepsy; investigational for ALS	Reduced seizure frequency; ALS trials ongoing
Ceftriaxone	Upregulates EAAT2 expression	ALS	Failed Phase III	Preclinical promise; no survival benefit in clinical trial

Why NMDA Antagonists Failed in Stroke Trials

Despite strong preclinical evidence, over 30 clinical trials of NMDA^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}2 receptor antagonists in acute stroke failed to demonstrate benefit Bhatt et al., 2009; Ikonomidou & Turski, 2002. Multiple factors contributed to this failure:

1. Therapeutic time window: In animal models, NMDA^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}3 antagonists were administered within minutes of ischemia onset, but in clinical trials treatment began 6-24 hours post-stroke, well after the excitotoxic cascade had peaked. The acute excitotoxic phase occurs within the first 1-2 hours.

2. Disruption of pro-survival signaling: Global NMDA^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}4 blockade eliminated neuroprotective synaptic receptor signaling alongside the targeted extrasynaptic excitotoxic signaling, potentially worsening outcomes after the acute phase.

3. Dose-limiting side effects: Competitive and high-affinity channel-blocking NMDA^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}5 antagonists produced psychotomimetic effects, sedation, and cardiovascular instability at neuroprotective doses, preventing adequate brain concentrations.

4. Cell-type non-selectivity: Broad NMDA^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}6 antagonism affected all neuron types equally, rather than selectively protecting vulnerable populations.

5. Trial design: Heterogeneous stroke populations, delayed enrollment, and insensitive outcome measures reduced statistical power Ikonomidou & Turski, 2002.

The success of memantine in Alzheimer’s Disease, by contrast, demonstrates that low-affinity, voltage-dependent NMDA^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}7 blockade can provide clinical benefit by preferentially blocking pathological tonic receptor activation while sparing phasic synaptic transmission Lipton, 2006.

Current Research Directions

Research continues to refine therapeutic strategies based on mechanistic understanding of excitotoxicity:

• GluN2B-selective antagonists: Compounds such as ifenprodil derivatives aim to block extrasynaptic GluN2B-containing receptors while preserving synaptic GluN2A signaling.

• EAAT2 upregulation: Small-molecule EAAT2 activators are being developed to enhance glutamate^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}8 clearance in ALS and other conditions.

• Combination therapy: Multi-target approaches combining glutamate^{5Ikonomidou & Turski, 20022002 · DOI 10.1016/S1474-4422(02Open reference}9 modulation with antioxidants or mitochondrial protectants aim to address the interconnected cascades downstream of calcium homeostasis disruption.

• Precision timing: Neuroprotective strategies are being paired with rapid stroke intervention (thrombectomy, thrombolysis) to deliver anti-excitotoxic agents within the narrow therapeutic window.

• Memantine

Brain Atlas Resources

• Allen Human Brain Atlas: Excitotoxicity expression search

• Allen Mouse Brain Atlas: Excitotoxicity search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Excitotoxicity developmental expression

Background

The study of Excitotoxicity has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways